glp 1 agonist crohn's disease Frontiers GLP-1 Use in Crohn's Disease:

Newer studies however, do not support the contention of a generalized defect in nutrient-related GLP-1 secretory responses in people with T2D, but rather suggest that the inter-individual differences in GLP-1 secretion, age of patients, duration of diabetes, concomitant drug therapy, and other variables play a role, and preclude definitive conclusions that diabetes is invariably associated with reduced GLP-1 secretion [22]

Initially approved for T2D management, GLP-1 RAs have also demonstrated cardiovascular and renal benefits [5,6,7]

Obesity is a complex, multifactorial disorder, characterized not only by excessive fat accumulation but also by its association with a wide range of complications

Key post hoc analysis of the landmark Steno-2 trial showing that intensified, multifactorial treatment slows progression of diabetic nephropathy and renal function loss in microalbuminuric patients with T2DM